Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against COVID-19.
According to the European Patent Office (EPO), in 2019 the number of patents filed in the pharmaceutical and biotechnology sectors rose for a third consecutive year.
Estar Technologies announced the Opposition Division of the European Patent Office (EPO) has revoked Regen Lab SA (Regenlab)'s platelet rich plasma (PRP) patent in its entirety due to lack of novelty and added matter.